April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Circulatory MicroRNAs in Serum as Potential Biomarkers for AMD
Author Affiliations & Notes
  • Anthony T Nguyen
    Ophthamology, University of California Davis, Davis, CA
  • Zeljka Smit-McBride
    Ophthamology, University of California Davis, Davis, CA
  • Matthew Bordbari
    Ophthamology, University of California Davis, Davis, CA
  • Amar P Patel
    Ophthamology, University of California Davis, Davis, CA
  • David Gregory Telander
    Ophthamology, University of California Davis, Davis, CA
  • Lawrence S Morse
    Ophthamology, University of California Davis, Davis, CA
  • Footnotes
    Commercial Relationships Anthony Nguyen, None; Zeljka Smit-McBride, None; Matthew Bordbari, None; Amar Patel, None; David Telander, None; Lawrence Morse, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1328. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Anthony T Nguyen, Zeljka Smit-McBride, Matthew Bordbari, Amar P Patel, David Gregory Telander, Lawrence S Morse; Circulatory MicroRNAs in Serum as Potential Biomarkers for AMD. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1328.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: The circulatory microRNAs in serum have recently been identified as novel biomarkers in a number of important chronic diseases. The aim of our study was to identify serum microRNA biomarkers for dry AMD and wet AMD compared to controls.

Methods: Serum samples from 40 patients of 4 different groups were collected. Group 1 were 10 age-matched normals with no ocular or systemic disease, Group 2 were 10 patients with category 3 high risk dry AMD, Group 3 were 10 new unilateral exudative AMD patients treated with Lucentis or Avastin, and Group 4 were 10 patients resistant to anti-VEGF therapy. RNA was isolated using modified Qiagen microRNeasy procedure and quantitated on BioAnalyzer’s small RNA chips. Microarray miRNA analysis of serum samples was performed on 4 samples from each group and ran on Affymetrix 2.0 miRNA arrays. Statistical analysis was done by ANOVA. Confirmatory quantitative real-time PCR (qPCR) using Exiqon's LNA™ Universal RT microRNA PCR, was done on the select set of biomarker candidates for the full sample set of each group. RNA spike-ins and melting curve analysis served as quality control, as well as serial dilutions to detect possible bias. Three microRNAs with stable expression in serum served as reference genes for data normalization. ANOVA was used for statistical analysis.

Results: Many statistically significant miRNA differences were seen between the 4 groups involving both increased and decreased levels. Total number of miRNAs with statistically significant differences in expression (p<0.01) are listed. The miRNAs showing largest dysregulations are listed in parentheses - up-regulated are listed first for each group comparison, followed by the down-regulated. Dry AMD vs. control had 10 (miR-661, miR-3121), wet AMD vs. control had 9 (miR-4258, miR-889), and resistant AMD vs. control had 9 (miR-438, miR-3261). Subsequent qPCR on the full sample sets showed a 6.8 fold increase in one of the members of the let-7 miRNA family, when Group 3 patients were compared to Group 4 patients (p<0.01). This family of miRNAs has been shown to be involved in the regulation of angiogenesis.

Conclusions: Our study indicates several potential biomarkers for dry and wet AMD, as well as potential biomarkers of resistance to anti-VEGF treatment. MiRNA levels that were significantly altered between the groups tested may offer diagnostic and therapeutic benefits.

Keywords: 412 age-related macular degeneration • 535 gene microarray • 440 candidate gene analysis  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×